Merck Investigational Zilovertamab Vedotin At 1.75 mg/kg Plus Standard Of Care Promising

 

• Merck (MRK, Financial) reports promising Phase 2 results for zilovertamab vedotin in relapsed/refractory DLBCL patients.
• The investigational drug achieved a 56.3% objective response rate, with an accompanying safety profile deemed manageable.
• Phase 3 portion of the trial is underway, supporting potential expansion in hematologic malignancies treatment.

https://www.gurufocus.com/news/2898325/mercks-investigational-zilovertamab-vedotin-at-175-mgkg-dose-plus-standard-of-care-showed-promising-antitumor-activity-including-complete-response-rate-in-patients-with-relapsedrefractory-dlbcl